Akorn Inc (AKRX)

33.21
0.00 (0.00)
NASDAQ : Health Care
Prev Close 33.21
Open 33.22
Day Low/High 33.21 / 33.26
52 Wk Low/High 17.57 / 47.35
Volume 201.44K
Avg Volume 4.30M
Exchange NASDAQ
Shares Outstanding 124.56M
Market Cap 4.14B
EPS 1.50
P/E Ratio 22.75
Div & Yield N.A. (N.A)

Latest News

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Akorn, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Akorn,...

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Akorn, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Akorn,...

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.

European Stocks High on French Perfume and Trump Bump

European Stocks High on French Perfume and Trump Bump

M&A, French election relief and renewed talk of reforms to taxes and trade all helped to push European stocks higher Tuesday

AKORN, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Investigates Sale To Fresenius Kabi

Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of Akorn, Inc.

Analysts' Actions -- Amazon, C.R. Bard, CyrusOne, Dow and More

Analysts' Actions -- Amazon, C.R. Bard, CyrusOne, Dow and More

Here are Tuesday's top research calls, including downgrades for Amazon and C.R. Bard, and new coverage of CyrusOne and Dow Chemical.

Fresenius and Merck Stocks Top DAX on Biosimilars Deal

Fresenius and Merck Stocks Top DAX on Biosimilars Deal

Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion and the biosimilars unit of German peer Merck KGaA.

Fresenius Kabi To Acquire Akorn

Fresenius Kabi has agreed to acquire Akorn (NASDAQ: AKRX), a U.S.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADS, AKRX, CSS, DISCA, GPS, LOCO Downgrades: CVTI, NCR Initiations: FLOW Read on to get TheStreet Quant Ratings' detailed report:

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

Finding the stocks that have changed direction.

2 Health-Care Stocks Ready to Break Out

2 Health-Care Stocks Ready to Break Out

Akorn and AmerisourceBergen are both flashing big moves, but in which direction is unclear.

Analysts' Actions -- FedEx, GoPro, Garmin, HP and More

Analysts' Actions -- FedEx, GoPro, Garmin, HP and More

Here are Monday's top research calls, including upgrades for FedEx, Garmin and HP, and a downgrade for GoPro.

7 Stocks Trending With Monster Volume

7 Stocks Trending With Monster Volume

Here's a technical look at how to play a number of stocks trending higher with strong volume.

Why Shares of Drug Maker Akorn Are a Buy After Losing 50% in 2016

Why Shares of Drug Maker Akorn Are a Buy After Losing 50% in 2016

Risk-tolerant investors should consider buying this stock on further dips.